Atara Biotherapeutics Inc... (ATRA)
6.60
-0.28 (-4.07%)
At close: Mar 28, 2025, 11:25 AM
Atara Biotherapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 128.94M | 8.57M | 63.57M | 20.34M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 21.01M | 8.89M | 14.57M | 11.38M | 9.87M | 8.11M | 3.78M | 956K | 383K | 48K | n/a | n/a | n/a |
| Gross Profit | 107.93M | -313K | 49.01M | 8.96M | -9.87M | -8.11M | -3.78M | -956K | -383K | -48K | n/a | n/a | n/a |
| Operating Income | -83.44M | -276.01M | -280.51M | -340.46M | -309.05M | -295.68M | -237.11M | -121.53M | -81.24M | -58.45M | -28.16M | -8.62M | -3.23M |
| Interest Income | 2.11M | 5.43M | 1.99M | 367K | 2.45M | 4.72M | 6.37M | 2.03M | 2.2M | 1.22M | 125K | 12K | n/a |
| Pretax Income | -85.42M | -276.11M | -228.29M | -340.1M | -306.61M | -290.96M | -230.74M | -119.5M | -79.04M | -57.23M | -28.03M | -8.6M | -12.28M |
| Net Income | -85.4M | -276.13M | -2.28B | -3.4B | -3.07B | -2.91B | -2.31B | -1.19B | -790.49M | -572.21M | -280.06M | -87.73M | -123.3M |
| Selling & General & Admin | 39.89M | 49.8M | 71.55M | 78.8M | 64.4M | 79.58M | 69.65M | 40.33M | 24.73M | 16.83M | 12.71M | 3.76M | 2.5M |
| Research & Development | 151.48M | 224.78M | 272.53M | 282M | 244.65M | 216.1M | 167.46M | 81.21M | 56.51M | 41.62M | 15.45M | 4.86M | 9.78M |
| Other Expenses | n/a | n/a | -700K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.07M | n/a | n/a |
| Operating Expenses | 191.37M | 275.69M | 344.09M | 360.8M | 309.05M | 295.68M | 237.11M | 121.53M | 81.24M | 58.45M | 28.16M | 8.62M | 12.28M |
| Interest Expense | 4.62M | 5.29M | 1.99M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | -1.11M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 212.38M | 284.58M | 344.09M | 360.8M | 309.05M | 295.68M | 237.11M | 121.53M | 81.24M | 58.45M | 28.16M | 8.62M | 12.28M |
| Income Tax | -12K | 15K | 12K | 46K | 15K | 12K | -44K | -14K | 10K | -9K | -25K | 170K | 51K |
| Shares Outstanding (Basic) | 7.49M | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K | 733.29K |
| Shares Outstanding (Diluted) | 7.49M | 4.24M | 4.08M | 3.75M | 2.96M | 2.05M | 1.75M | 1.19M | 1.15M | 1.02M | 199.44K | 38.63K | 733.29K |
| EPS (Basic) | -11.41 | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 | -227.09 | -16.81 |
| EPS (Diluted) | -11.41 | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 | -100.03 | -68.78 | -55.92 | -140.42 | -227.09 | -16.81 |
| EBITDA | -75.75M | -266M | -213.72M | -331.12M | -296.74M | -282.86M | -233.33M | -120.58M | -80.86M | -58.4M | -28.15M | -8.61M | -4.09M |
| Depreciation & Amortization | 5.05M | 4.83M | 14.57M | 11.38M | 9.87M | 8.11M | 3.78M | 956K | 383K | 48K | 6K | 4K | 3.23M |